Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings, Inc. (XERS) is a pioneering biopharmaceutical company dedicated to developing and commercializing innovative therapies that address unmet medical needs in endocrinology, neurology, and gastroenterology. Headquartered in the United States, Xeris leverages its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, patient-friendly injectable therapeutics. These technologies enable the development of ultra-low volume, stable formulations that eliminate the need for reconstitution, refrigeration, or complex preparation, significantly improving patient convenience and compliance.
Core Commercial Products
Xeris has successfully brought to market three FDA-approved therapies that exemplify its commitment to innovation:
- Gvoke: A ready-to-use liquid glucagon designed for the treatment of severe hypoglycemia, offering a convenient and reliable solution for patients with diabetes.
- Keveyis: The first FDA-approved therapy for primary periodic paralysis, a rare and debilitating neuromuscular disorder.
- Recorlev: Approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome, addressing a critical need in endocrine care.
Proprietary Technologies
At the heart of Xeris's innovation are its proprietary formulation platforms:
- XeriSol: A formulation technology that enables the creation of ready-to-use, stable solutions for injectable drugs that would otherwise require reconstitution or refrigeration.
- XeriJect: A cutting-edge platform designed for ultra-low volume injectables, allowing for the development of biotherapeutics that are easier to administer and potentially less painful for patients. This technology holds promise for improving the delivery of complex biologics and other challenging formulations.
These platforms not only underpin Xeris's existing product portfolio but also drive its pipeline of development programs, positioning the company as a leader in patient-centric drug delivery solutions.
Pipeline and Growth Potential
In addition to its commercialized products, Xeris maintains a robust pipeline of development programs aimed at expanding its therapeutic offerings and addressing additional unmet medical needs. By applying its XeriSol and XeriJect technologies, the company is exploring new formulations and indications that could further differentiate its portfolio in the competitive biopharma landscape.
Market Position and Competitive Landscape
Xeris operates in the highly competitive pharmaceutical and biotechnology industry, where innovation, regulatory compliance, and market access are critical to success. Its differentiation lies in its focus on ready-to-use formulations and ultra-low volume injectables, which address significant pain points in traditional drug delivery methods. This unique value proposition allows Xeris to compete effectively against larger pharmaceutical companies and other biotech firms, particularly in niche markets with high unmet needs.
Challenges and Opportunities
Like many biopharma companies, Xeris faces challenges such as navigating complex regulatory pathways, ensuring successful commercialization of its therapies, and maintaining a steady pipeline of new products. However, its proprietary technologies and focus on patient-centric solutions provide a strong foundation for sustained innovation and market relevance.
In summary, Xeris Biopharma Holdings is a forward-thinking biopharmaceutical company that combines scientific expertise with proprietary technologies to deliver groundbreaking therapies. Its commitment to addressing unmet medical needs through innovative drug delivery systems positions it as a significant player in the biopharma industry.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced its Q2 financial results for 2021, showcasing a 32% increase in Gvoke net sales, totaling $8.8 million. The company reported a net loss of $27.5 million, improving from a loss of $24.1 million in Q2 2020. The proposed acquisition of Strongbridge Biopharma is anticipated to close in Q4 2021, with a cash position of $116 million. Gvoke's prescription volume surged, reaching over 21,000, and a partnership with Tetris Pharma aims to commercialize Ogluo in Europe, potentially adding up to $71 million in future payments.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) reported its issued share capital as of July 28, 2021, consisting of 66,497,370 shares of common stock. The company also noted 5,081,323 stock options, 2,059,762 restricted stock units, 94,012 warrants, and $47,175,000 in convertible notes due 2025. Xeris, known for its innovative injectable therapeutic solutions, has technologies that improve the ease and stability of drug administration, including its commercial product, Gvoke®. The announcement also highlights upcoming SEC filings related to the acquisition of Strongbridge Biopharma.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) will release its second quarter 2021 financial results on August 5, 2021, before the U.S. market opens. A conference call will be held at 8:30 a.m. ET to discuss financial and operational results. Xeris specializes in ready-to-use injectable formulations, with its proprietary technologies such as XeriSol™ and XeriJect™, aimed at simplifying administration and enhancing stability. The company's first commercial product is Gvoke®. Investors can register for the call and access a replay later.
Xeris Pharmaceuticals (Nasdaq: XERS) announced executive changes to strengthen its commercial strategy, particularly ahead of the acquisition of Strongbridge Biopharma. CFO Barry Deutsch has stepped down but will assist during the transition until the merger's expected completion in Q4 2021. Steven Pieper, with 20 years of healthcare finance experience, has been promoted to CFO. He previously helped launch Xeris's first commercial product, Gvoke®. The company continues to focus on innovative, ready-to-use injectable drug formulations to enhance patient care.
Xeris Pharmaceuticals (Nasdaq: XERS) has entered an exclusive agreement with Tetris Pharma for the commercialization of Ogluo® in the European Economic Area, the UK, and Switzerland, aimed at treating severe hypoglycaemia in diabetes patients. Xeris is set to receive up to $71 million in milestone payments and royalties on net sales. The partnership is expected to enhance Ogluo's accessibility to insulin-dependent diabetes patients, where the demand is significant, yet current glucagon prescriptions remain low.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) disclosed that on July 1, 2021, it granted 80,250 restricted stock units to 37 new employees through its Inducement Equity Plan. This plan targets new hires as incentives for accepting employment. The stock options will vest over four years, with various vesting schedules based on employment duration. Xeris specializes in ready-to-use injectable formulations, aiming to simplify medication delivery and reduce healthcare costs. Its proprietary technologies, XeriSol™ and XeriJect™, enhance stability and ease of use for patients and providers.
Xeris Pharmaceuticals (XERS) has announced an agreement to acquire Strongbridge Biopharma (SBBP) for approximately $267 million in stock and contingent value rights (CVRs). Strongbridge shareholders will receive a fixed exchange ratio of 0.7840 shares of the new entity, Xeris Biopharma Holdings, and potential CVRs based on sales milestones of KEVEYIS® and RECORLEV®. This merger aims to create a diversified biopharmaceutical company focused on rare diseases, enhancing revenue growth with commercial assets like Gvoke® and RECORLEV®. The transaction is expected to close in Q4 2021.
Xeris Pharmaceuticals (XERS) announced its acquisition of Strongbridge Biopharma (SBBP) for approximately $267 million, combining their operations into Xeris Biopharma Holdings. Strongbridge shareholders will receive 0.7840 shares of Xeris for each of their shares, translating to about $2.72 per share, a 12.9% premium. Contingent value rights (CVRs) could add up to $1.00 per share based on sales targets for KEVEYIS and RECORLEV. Post-acquisition, current Xeris shareholders will hold 60% of the company.
Xeris Pharmaceuticals has announced a definitive agreement to acquire Strongbridge Biopharma for approximately $267 million, including stock and contingent value rights (CVRs). The transaction values Strongbridge at about $2.72 per share, reflecting a 12.9% premium based on its closing price on May 21, 2021. The deal, unanimously approved by both companies' boards, is expected to close in early Q4 2021. This merger will create Xeris Biopharma Holdings, combining their product portfolios and commercial infrastructures to enhance revenue growth and operational efficiencies in the specialty and rare disease markets.
Xeris Pharmaceuticals, Inc. (XERS) reported its first quarter 2021 results, highlighting strong financial performance despite pandemic challenges. Gvoke prescriptions exceeded 16,000, marking over 400% growth year-over-year. The company received EU approval for Ogluo and is targeting a Q4 2021 launch. Financially, Gvoke net sales reached $8.1 million, with a net loss of $18.4 million, improved from $29.2 million in the same quarter last year. As of March 31, 2021, Xeris held $135.9 million in cash and equivalents. Management is optimistic about market stability and product development.
FAQ
What is the current stock price of Xeris Biopharma Holdings (XERS)?
What is the market cap of Xeris Biopharma Holdings (XERS)?
What does Xeris Biopharma Holdings do?
What are Xeris's proprietary technologies?
What products has Xeris Biopharma commercialized?
What makes Xeris Biopharma unique in the biopharma industry?
What challenges does Xeris Biopharma face?
What is XeriJect technology?
What therapeutic areas does Xeris focus on?
How does Xeris generate revenue?
What is the significance of XeriSol technology?
Who are Xeris's competitors?
